Exploring the Olfactory Mucosa, Blood and Urine for the Identification of Early Biomarkers of Parkinson's Disease, Atypical Parkinsonisms and Neurocognitive Disorders Due to Lewy Body Disease

Launched by FONDAZIONE I.R.C.C.S. ISTITUTO NEUROLOGICO CARLO BESTA · Feb 20, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating new ways to identify early signs of Parkinson's disease and related conditions, such as multiple system atrophy and Lewy body dementia. Researchers are looking to study samples from the olfactory mucosa (the tissue responsible for our sense of smell), blood, and urine of patients to find specific markers that can help in diagnosing these diseases more accurately. The goal is to use advanced techniques to detect proteins that are linked to these conditions, which may improve early diagnosis and treatment options.

To participate in this trial, individuals must have a diagnosis of Parkinson's disease, multiple system atrophy, or Lewy body dementia, among other related neurological disorders. There are no specific exclusions for this study. Participants can expect to provide samples of their olfactory mucosa, blood, and urine, which will be analyzed to look for potential biomarkers associated with these diseases. This research is an exciting step toward better understanding and diagnosing neurodegenerative diseases, ultimately benefiting patients and their families.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • PD (Postuma et al., 2015), MSA (Palma et al., 2018), DLB (McKeith et al., 2017), OND including acquired and hereditary ataxic syndrome with known etiology, progressive supranuclear palsy, corticobasal degeneration, and motor neuron disease.
• Exclusion Criteria:
• • na